About Us > Corporate Collaborations

Proteolix is committed to developing and commercializing its current lead drug, carfilzomib (PR-171), as well as continuing the advancement of its earlier-stage programs. The company will consider selective corporate alliances for the co-development of carfilzomib outside of the United States.